- Insys Therapeutics (INSY +0.5%) Q3 results: Revenues: $91.3M (+56.6%); R&D Expense: $12.3M (+75.7%); SG&A: $32.9M (+27.0%); Operating Income: $39.1M (+95.5%); Net Income: $26.1M (+127.0%); EPS: $0.34 (+112.5%); Non-GAAP EPS: $0.50 (+56.3%); Quick Assets: $155.5M (+87.6%).
- No guidance given.